Similarities and differences between IBS-C and FC with regards to symptomatology, sleep quality and psychological attributes.
Similarities and differences between IBS-C and FC with regards to symptomatology, sleep quality and psychological attributes. J Formos Med Assoc. 2019 Mar 25;: Authors: Chen HD, Bair MJ, Chang WC, Hsu CS, Wong MW, Hung JS, Liu TT, Yi CH, Lei WY, Chen CL Abstract BACKGROUND: Irritable bowel syndrome (IBS) and functional constipation (FC) are highly prevalent in the general population and have signiﬁcant symptom overlap, while the clinical associations and psychological links between IBS and FC remains poorly understood. We aimed to compare the clinical, metabolic and psychological factors between patients with FC patients and constipation predominated IBS. METHODS: We consecutively enrolled 360 patients from the outpatient clinics of Hualien Tzu Chi medical center. Constipation-predominant IBS (IBS-C) and FC were diagnosed based on Rome III criteria. All participants completed the Pittsburg Sleep Quality Index (PSQI) score, the State Trait Anxiety Inventory (STAI) score and the Taiwanese Depression Questionnaire (TDQ) score. RESULTS: Fifty-four patients had FC and twenty-three patients had IBS-C. Compared to asymptomatic controls, FC/IBS-C groups had female predominance (p
ConclusionCiprofol has potential for clinical application for continuous intravenous infusion to maintain sedation for 12 h with the same safety, tolerability and efficacy as propofol.
A headband worn for 20 minutes before bedtime may help beat insomnia. One person in ten in the UK has difficulty getting to sleep or staying asleep, with women twice as likely to be affected as men.
CONCLUSION/RELEVANCEThe periprocedural complication risk for edoxaban treated patients undergoing pacemaker or invasive cardiac monitoring implantation was low. This population of patients was well managed in routine practice.This article is protected by copyright. All rights reserved
The deal, with Osaka-based Sumitomo Dainippon Pharma Co., is for the companies to develop and commercialize prescription digital therapies and general wellness products for the treatment of anxiety disorders.